ImmunityBio
IBRX
126 hedge funds and large institutions have $381M invested in ImmunityBio in 2021 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 20 closing their positions.
145% more capital invested
Capital invested by funds: $155M → $381M (+$226M)
110% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 20
21% more funds holding
Funds holding: 104 → 126 (+22)
19% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 32
6.55% less ownership
Funds ownership: 10.75% → 4.19% (-6.6%)
53% less call options, than puts
Call options by funds: $24M | Put options by funds: $50.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$43.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.8M |
| 3 |
Rafferty Asset Management
New York
|
+$12.1M |
| 4 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
+$9M |
| 5 |
BlackRock
New York
|
+$6.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$8.63M |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$2.39M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.5M |
| 4 |
Bank of New York Mellon
New York
|
-$1.38M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$1.04M |
IBRX Hedge Fund Activity: Q1 2021 in Review
126 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2021, worth a combined $381M — up 145% from $155M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new IBRX positions and 20 closed out — a net gain of 22 holders — while 38 added to existing stakes and 32 trimmed.
The largest buyer was State Street, adding an estimated $43.2M. The largest seller was Invesco, cutting an estimated $8.63M.
- 126 institutional investors held ImmunityBio (IBRX) as of Q1 2021, up from 104 in Q4 2020.
- Funds reported $381M of ImmunityBio stock for Q1 2021, up 145% quarter-over-quarter.
- 42 funds opened new ImmunityBio positions in Q1 2021 and 20 closed out, a net change of +22 holders.
- The largest ImmunityBio buyer in Q1 2021 was State Street, an estimated $43.2M added.
- The largest ImmunityBio seller in Q1 2021 was Invesco, an estimated $8.63M sold.
Based on aggregated 13F filings for Q1 2021.